Changes in T cell subsets identify responders to FcR non-binding anti-CD3 mAb (teplizumab) in patients with Type 1 diabetes

The mechanisms whereby immune therapies affect progression of Type 1 diabetes (T1D) are not well understood. Teplizumab, an FcR non-binding anti-CD3 mAb, has shown efficacy in multiple randomized clinical trials. We previously reported an increase in the frequency of circulating CD8+ central memory...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Immunol
Egile Nagusiak: Tooley, James E, Vudattu, Nalini, Choi, Jinmyung, Cotsapas, Chris, Devine, Lesley, Raddassi, Khadir, Ehlers, Mario R, McNamara, James G, Harris, Kristina M, Kanaparthi, Sai, Phippard, Deborah, Herold, Kevan C
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882099/
https://ncbi.nlm.nih.gov/pubmed/26518356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/eji.201545708
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak